Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study
- 23 September 2016
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 24 (2) , 418-424
Abstract
The American College of Surgeons Oncology Group Z1031 trial demonstrated that neoadjuvant endocrine therapy (NET) increased breast-conserving surgery (BCS)Keywords
This publication has 11 references indexed in Scilit:
- Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast CancerAnnals of Surgical Oncology, 2011
- Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031Journal of Clinical Oncology, 2011
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Annals of Oncology, 2009
- Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapyBreast Cancer Research and Treatment, 2008
- Neoadjuvant endocrine therapy in breast cancerThe Breast, 2006
- Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized TrialJournal of Clinical Oncology, 2005
- Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized TrialJNCI: Journal of the National Cancer Institute, 2002
- Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyAnnals of Oncology, 2001
- Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized TrialJournal of Clinical Oncology, 2001
- Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast CancerJournal of Clinical Oncology, 1999